LON:ONC Oncimmune (ONC) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Oncimmune Stock (LON:ONC) Get Oncimmune alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume589,365 shsMarket Capitalization£1.29 millionP/E Ratio0.13Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom. Read More Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONC Stock News HeadlinesLiquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta ...October 6, 2025 | uk.finance.yahoo.comOncimmune Holdings Faces Administration and Adviser ResignationsMarch 26, 2025 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 13 at 1:00 AM | Banyan Hill Publishing (Ad)Oncimmune Holdings to Enter Administration and Suspend TradingMarch 17, 2025 | tipranks.comOncimmune Share Chat (ONC)February 26, 2025 | lse.co.ukOncimmune Holdings Full Year 2024 Earnings: Misses ExpectationsFebruary 18, 2025 | finance.yahoo.comOncimmune schedules General Meeting for March approvalFebruary 12, 2025 | msn.comOncimmune forecasts 33% revenue growth in 2025 after doubling in 2024February 10, 2025 | lse.co.ukSee More Headlines ONC Stock Analysis - Frequently Asked Questions How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) released its quarterly earnings data on Monday, February, 10th. The company reported ($4.72) EPS for the quarter. Oncimmune had a positive trailing twelve-month return on equity of 416.53% and a negative net margin of 132.46%. How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE). Company Calendar Last Earnings2/10/2025Today8/13/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:ONC CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX 8.87 Trailing P/E Ratio0.13 Forward P/E RatioN/A P/E GrowthN/ANet Income£10.79 million Net Margins-132.46% Pretax MarginN/A Return on Equity416.53% Return on Assets-26.38% Debt Debt-to-Equity Ratio-213.51 Current Ratio0.69 Quick Ratio0.63 Sales & Book Value Annual Sales£1.86 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow11.96 Book ValueGBX (1.72) per share Price / BookN/AMiscellaneous Outstanding Shares113,304,985Free FloatN/AMarket Cap£1.29 million OptionableNot Optionable Beta1.19 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:ONC) was last updated on 8/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
